News

New Phase 3 Trial of Blisibimod for Severe Lupus Begins

Anthera Pharmaceuticals reported that the company’s Phase 3 clinical trial of blisibimod in patients with severe systemic lupus erythematosus (SLE) began recently with researchers screening the study’s first patient. Called CHABLIS 7.5, the study is the second Phase 3 trial to explore the drug in lupus patients with and without lupus…

Initial Data on Candidate for Autoimmune Disease Reported

Dutch biopharmaceutical company Argenx recently reported initial data from its Phase 1 multiple ascending dose clinical trial of ARGX-113 in healthy volunteers. ARGX-113 is designed for the management of acute autoimmune crisis (sudden and severe onset of symptoms between periods of remission) and could potentially be used for many rare medical…

Trigger May Be Uncovered For Lupus, Other Autoimmune Diseases

Scientists at the Hospital for Special Surgery (HSS) in New York, in collaboration with Greek researchers, may have identified a trigger for autoimmune disorders that could shed light on how many diseases develop, including lupus. The investigators found virus-like components of the human genome that seem to be…

2016 Lupus Insight Prize Goes to University of Massachusetts Professor

Ann Marshak-Rothstein, professor of Medicine and Rheumatology at University of Massachusetts Memorial Medical School, received the 2016 Lupus Insight Prize for promising research to improve the treatment of the lupus-related skin disease called cutaneous lupus. The award was announced at the recent 16th Annual Meeting of the Federation of Clinical…